OpenURL Connection Search

Select item for more details and to access through your institution.

Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Published in:
2000
By:
- Kern, W;
- Schoch, C;
- Haferlach, T;
- Braess, J;
- Unterhalt, M;
- Wörmann, B;
- Büchner, T;
- Hiddemann, W
Publication type:
journal article
Oral idarubicin pharmacokinetics -- correlation of trough level with idarubicin area under curve.
Published in:
Leukemia (08876924), 1997, v. 11, p. S15
By:
- Schleyer, E.;
- Kühn, S.;
- Rührs, H.;
- Unterhalt, M.;
- Kaufmann, C. C.;
- Kern, W.;
- Braess, J.;
- Sträubel, G.;
- Hiddemann, W.
Publication type:
Article
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Published in:
2001
By:
- Kern, Wolfgang;
- Schleyer, Eberhard;
- Braess, Jan;
- Wittmer, Ellen;
- Ohnesorge, Jörn;
- Unterhalt, Michael;
- Wörmann, Bernhard;
- Büchner, Thomas;
- Hiddemann, Wolfgang;
- Kern, W;
- Schleyer, E;
- Braess, J;
- Wittmer, E;
- Ohnesorge, J;
- Unterhalt, M;
- Wörmann, B;
- Büchner, T;
- Hiddemann, W
Publication type:
journal article
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
Published in:
2000
By:
- Feuring-Buske, M.;
- Kneba, M.;
- Unterhalt, M.;
- Engert, A.;
- Gramatzki, M.;
- Hiller, E.;
- Trümper, L.;
- Brugger, W.;
- Ostermann, H.;
- Atzpodien, J.;
- Hallek, M.;
- Aulitzky, E.;
- Hiddemann, W.;
- Trümper, L
Publication type:
journal article
Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma.
Published in:
2000
By:
- Feuring-Buske, M.;
- Buske, C.;
- Unterhalt, M.;
- Hiddemann, W.
Publication type:
journal article
Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.
Published in:
Leukemia (08876924), 2014, v. 28, n. 5, p. 1001, doi. 10.1038/leu.2013.297
By:
- Fiegl, M;
- Unterhalt, M;
- Kern, W;
- Braess, J;
- Spiekermann, K;
- Staib, P;
- Grüneisen, A;
- Wörmann, B;
- Schöndube, D;
- Serve, H;
- Reichle, A;
- Hentrich, M;
- Schiel, X;
- Sauerland, C;
- Heinecke, A;
- Rieger, C;
- Beelen, D;
- Berdel, W E;
- Büchner, T;
- Hiddemann, W
Publication type:
Article
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
Published in:
Leukemia (08876924), 2009, v. 23, n. 1, p. 153, doi. 10.1038/leu.2008.261
By:
- Buske, C;
- Hoster, E;
- Dreyling, M;
- Eimermacher, H;
- Wandt, H;
- Metzner, B;
- Fuchs, R;
- Bittenbring, J;
- Woermann, B;
- Hohloch, K;
- Hess, G;
- Ludwig, W-D;
- Schimke, J;
- Schmitz, S;
- Kneba, M;
- Reiser, M;
- Graeven, U;
- Klapper, W;
- Unterhalt, M;
- Hiddemann, W
Publication type:
Article
AML1–ETO meets JAK2: clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia.
Published in:
2007
By:
- Schneider, F.;
- Bohlander, S. K.;
- Schneider, S.;
- Papadaki, C.;
- Kakadyia, P.;
- Dufour, A.;
- Vempati, S.;
- Unterhalt, M.;
- Feuring-Buske, M.;
- Buske, C.;
- Braess, J.;
- Wandt, H.;
- Hiddemann, W.;
- Spiekermann, K.
Publication type:
Letter
RITUXIMAB IN COMBINATION WITH BENDAMUSTINE OR HIGH‐DOSE CYTARABINE‐BASED INDUCTION THERAPY IN TRANSPLANT‐ELIGIBLE PATIENTS WITH MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.62_2880
By:
- Villa, D.;
- Hoster, E.;
- Hermine, O.;
- Klapper, W.;
- Szymczyk, M.;
- Bosly, A.;
- Unterhalt, M.;
- Freeman, C. L.;
- Scott, D. W.;
- Gerrie, A. S.;
- Savage, K. J.;
- Sehn, L. H.;
- Dreyling, M.
Publication type:
Article
SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS.
Published in:
Hematological Oncology, 2019, v. 37, p. 118, doi. 10.1002/hon.78_2629
By:
- Stathis, A.;
- Mey, U.;
- Schär, S.;
- Hitz, F.;
- Pott, C.;
- Mach, N.;
- Krasniqi, F.;
- Novak, U.;
- Schmidt, C.;
- Hohloch, K.;
- Kienle, D.;
- Hess, D.;
- Moccia, A.;
- Unterhalt, M.;
- Eckhardt, K.;
- Hayoz, S.;
- Rossi, D.;
- Dirnhofer, S.;
- Ceriani, L.;
- Bertoni, F.
Publication type:
Article
AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST REMISSION SIGNIFICANTLY PROLONGS PROGRESSION‐FREE AND OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 43, doi. 10.1002/hon.13_2629
By:
- Zoellner, A.;
- Unterhalt, M.;
- Stilgenbauer, S.;
- Hübel, K.;
- Thieblemont, C.;
- Metzner, B.;
- Kluin‐Nelemans, H.;
- Hiddemann, W.;
- Dreyling, M.;
- Hoster, E.
Publication type:
Article
SAKK 35/15: A PHASE I TRIAL OF OBINUTUZUMAB IN COMBINATION WITH VENETOCLAX IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA PATIENTS.
Published in:
Hematological Oncology, 2019, v. 37, p. 118, doi. 10.1002/hon.78_2629
By:
- Stathis, A.;
- Mey, U.;
- Schär, S.;
- Hitz, F.;
- Pott, C.;
- Mach, N.;
- Krasniqi, F.;
- Novak, U.;
- Schmidt, C.;
- Hohloch, K.;
- Kienle, D.;
- Hess, D.;
- Moccia, A.;
- Unterhalt, M.;
- Eckhardt, K.;
- Hayoz, S.;
- Rossi, D.;
- Dirnhofer, S.;
- Ceriani, L.;
- Bertoni, F.
Publication type:
Article
AUTOLOGOUS STEM CELL TRANSPLANTATION IN FIRST REMISSION SIGNIFICANTLY PROLONGS PROGRESSION‐FREE AND OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 43, doi. 10.1002/hon.13_2629
By:
- Zoellner, A.;
- Unterhalt, M.;
- Stilgenbauer, S.;
- Hübel, K.;
- Thieblemont, C.;
- Metzner, B.;
- Kluin‐Nelemans, H.;
- Hiddemann, W.;
- Dreyling, M.;
- Hoster, E.
Publication type:
Article
RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO.
Published in:
Hematological Oncology, 2017, v. 35, p. 32, doi. 10.1002/hon.2437_12
By:
- Hoster, E.;
- Unterhalt, M.;
- Hänel, M.;
- Prange ‐ Krex, G.;
- Forstpointner, R.;
- Florschütz, A.;
- Graeven, U.;
- Frickhofen, N.;
- Wulf, G.;
- Lengfelder, E.;
- Lerchenmüller, C.;
- Schlag, R.;
- Dierlamm, J.;
- Fischer Von Weikersthal, L.;
- Ahmed, A.;
- Harich, H.;
- Rosenwald, A.;
- Klapper, W.;
- Dreyling, M.;
- Hiddemann, W.
Publication type:
Article
HIGHER MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2017, v. 35, p. 97, doi. 10.1002/hon.2437_86
By:
- Alig, S.;
- Jurinovic, V.;
- Dreyling, M.;
- Pastore, A.;
- Kridel, R.;
- Gascoyne, R.;
- Hiddemann, W.;
- Unterhalt, M.;
- Hoster, E.;
- Weigert, O.
Publication type:
Article
Aktuelle Therapiestrategien beim follikulären Lymphom.
Published in:
Der Internist, 2016, v. 57, n. 3, p. 222, doi. 10.1007/s00108-015-0009-3
By:
- Hiddemann, W.;
- Hoster, E.;
- Schmidt, C.;
- Dreyling, M.;
- Unterhalt, M.
Publication type:
Article
Therapie des Mantelzelllymphoms.
Published in:
Der Internist, 2007, v. 48, n. 4, p. 382, doi. 10.1007/s00108-007-1803-3
By:
- Dreyling, M.;
- Unterhalt, M.;
- Weigert, O.;
- Hiddemann, W.
Publication type:
Article
Therapie des follikulären Lymphoms.
Published in:
Der Internist, 2007, v. 48, n. 4, p. 372, doi. 10.1007/s00108-007-1804-2
By:
- Buske, C.;
- Unterhalt, M.;
- Hiddeman, W.
Publication type:
Article
Antikörpertherapie maligner Lymphome.
Published in:
Der Internist, 2004, v. 45, n. 12, p. 1370, doi. 10.1007/s00108-004-1299-z
By:
- Buske, C.;
- Dreyling, M.;
- Unterhalt, M.;
- Hiddemann, W.
Publication type:
Article

Found: 19